Can Addex Therapeutics Maintain Its Cost-Cutting Momentum In Q2?
Addex Therapeutics (ADXN) will report Q2 2026 results on September 28, 2026. Q1 2026 saw a net loss of CHF 1.71 million, with R&D and admin expenses down. Neurosterix, a spin-out, is advancing NTX-253 for schizophrenia. ADXN raised $2.8 million in August 2026, extending cash runway. Q2 2025 had a net loss of CHF 1.84 million. ADXN stock is at $3.45.
How this was made
The 30-second read
Why it matters
Q1 results show widening loss and reduced cash, but the $2.8M ATM raise extends runway, setting the stage for Q2 performance expectations.
Market read
Micro‑cap biotech investors will watch the Q2 earnings call for guidance on cash burn and pipeline milestones.
What to watch
Potential upside from Neurosterix spin‑out progress and IND‑enabling studies with partner Indivior.
Background
Addex Therapeutics (ADXN) is a clinical‑stage biotech developing allosteric modulators for neurological disorders.
Ticker impact
Addex Therapeutics disclosed Q1 2026 loss, cash position and an $2.8M ATM raise, and previewed its Q2 earnings scheduled for Sep 28.
Potential short‑term pressure on ADXN as investors digest the widening loss, with upside if Q2 guidance beats expectations.
The disclosed loss and modest cash balance are material for a micro‑cap biotech; the ATM raise is modest, so price reaction is likely limited but negative bias remains.
Market effects
Highlights continued cash constraints in early‑stage neuro‑pharma, may pressure peer small‑cap biotech valuations.
Swiss‑listed biotech sector sees modest negative sentiment.
Limited to niche neuro‑pharma investors.
Counterpoint
The ATM raise could be seen as a confidence signal, suggesting management believes upcoming data will justify the dilution.
Key entities
- companyAddex Therapeutics
Clinical‑stage biotech developing neuro‑pharma candidates.
- affiliateNeurosterix US Holdings LLC
Spin‑out holding 20% equity, advancing M4 modulator programs.
